Unity Biotechnology, Inc. (0YC0.L) LSE

0.06

+0(+0.00%)

Updated at September 05 04:59PM

Currency In USD

Unity Biotechnology, Inc.

Address

285 East Grand Avenue

South San Francisco, CA 94080

United States of America

Phone

650 416 1192

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

16

First IPO Date

October 04, 2018

Key Executives

NameTitlePayYear Born
Dr. Anirvan Ghosh Ph.D.Chief Executive Officer & Director953,7061965
Dr. Nathaniel E. David A.B., Ph.D.Co-Founder & Independent Director49,5001968
Mr. Alexander Hieu Nguyen J.D.Chief Legal Officer & Head of Operations622,9681978
Ms. Alicia Tozier M.B.A.Chief Strategy Officer0N/A
Dr. Przemyslaw Sapieha Ph.D.Chief Scientist0N/A
Dr. Jan M. van Deursen Ph.D.Founder0N/A
Dr. Federico Grossi M.D., Ph.D.Chief Medical Officer01974

Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.